Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma

NCT00091091 | Completed

• 4 other identifiers: ALTE04N1COG-ALTE04N1CDR0000383244NCI-2009-00381
• Study Type: observational
• Target: 530
• Locations: 1 country
• Sites: 15

Brief Summary

RATIONALE: Assessing the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care. PURPOSE: This clinical trial is studying the long-term effects of treatment in patients who were previously treated for childhood Hodgkin's lymphoma.

Conditions

Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma

Keywords

long-term effects secondary to cancer therapy in children; stage I childhood Hodgkin lymphoma; stage II childhood Hodgkin lymphoma; stage III childhood Hodgkin lymphoma; stage IV childhood Hodgkin lymphoma

Outcome Measures

Primary Outcomes (1)

• Risk for a specific adverse condition until the earliest of death, development of the adverse condition, loss to follow up, or completion of questionnaire

  The calculation of the incidence rates will be done in two ways: (a) using the self-report incidence of adverse conditions; and (b) using the incidence of adverse conditions validated by clinical evaluation.

  length of study

Study Arms (1)

All patients

Self report/Medical record review/ clinical eval

Other: medical chart review; Other: questionnaire administration; Procedure: management of therapy complications

Interventions

medical chart review OTHER

All patients

questionnaire administration OTHER

All patients

management of therapy complications PROCEDURE

All patients

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Treatment for primary Hodgkin disease at any one of the participating institutions 1987 - onward, or patients otherwise eligible and currently followed at one of the participating institutions.

DISEASE CHARACTERISTICS: * Contemporary cohort * At least 5 years since diagnosis of Hodgkin's lymphoma * Diagnosed between the years 1987-2001 * 21 and under at diagnosis * No evidence of disease * Prior treatment on 1 of the following protocols during the years 1987-2001: * Children's Cancer Group (CCG) CCG-5942, CCG-59704 * Pediatric Oncology Group (POG) POG-8625, POG-8725, POG-9425, POG-9426 * Pediatric Hodgkin's Consortium: VAMP, VEPA, VAMP/COP * Institutional protocols COPP/ABV, MOPP/ABVD, ABVD * Childhood Cancer Survivor Study (CCSS) Hodgkin's lymphoma cohort * Current enrollment in the CCSS * Diagnosed between the years 1976-1986 * Completed baseline questionnaire at comparable timepoints (as the contemporary cohort) after diagnosis PATIENT CHARACTERISTICS: Age * Any age Performance status * Not specified Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Children's Oncology Group: lead
• National Cancer Institute (NCI): collaborator

Study Sites (15)

Lucile Packard Children's Hospital at Stanford University Medical Center

Palo Alto, California, 95798, United States

Location

Yale Cancer Center

New Haven, Connecticut, 06520-8028, United States

Location

University of Chicago Cancer Research Center

Chicago, Illinois, 60637-1470, United States

Location

Hackensack University Medical Center Cancer Center

Hackensack, New Jersey, 07601, United States

Location

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center

New York, New York, 10032, United States

Location

Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States

Location

James P. Wilmot Cancer Center at University of Rochester Medical Center

Rochester, New York, 14642, United States

Location

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229-3039, United States

Location

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104-9786, United States

Location

Rhode Island Hospital Comprehensive Cancer Center

Providence, Rhode Island, 02903, United States

Location

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

Location

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232-6838, United States

Location

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

Dallas, Texas, 75390, United States

Location

Children's Hospital and Regional Medical Center - Seattle

Seattle, Washington, 98105, United States

Location

St. Vincent Hospital Regional Cancer Center

Green Bay, Wisconsin, 54307-3508, United States

Location

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Debra L. Friedman, MD, MS

  Vanderbilt-Ingram Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 7, 2004
• First Posted: September 8, 2004
• Study Start: December 1, 2004
• Primary Completion: June 27, 2011
• Last Updated: July 16, 2018

Record last verified: 2017-02

Locations

US (15)